AlphaFold 2 2
Predicts the 3D structure of a protein from its amino-acid sequence at near-experimental accuracy; the AlphaFold Protein Structure Database (with EMBL-EBI) provides predicted structures for over 200 million proteins, including cancer-relevant targets and mutants.
At a glance
What it does
Sequence in, atomic coordinates and per-residue confidence (pLDDT) out. In oncology it underpins structural interpretation of driver mutations, target druggability assessment and structure-based drug design.
Notable uses in oncology
CASP14 winner (2020); more than 30% of publications citing AlphaFold concern disease research, including analyses of mutated cancer proteins; feeds Isomorphic Labs' drug-design work.
Tasks, data types and cancers
Architecture
Training data
Experimentally determined structures from the Protein Data Bank (cut-off 2018) plus self-distillation on predicted structures of UniRef sequences.
Linked datasets
- training Protein Data Bank (wwPDB / RCSB) Open download
Evaluation
| Benchmark / dataset | Metric | Value | External validation | Source |
|---|---|---|---|---|
| CASP14 | GDT_TS | median 92.4 across targets | yes | Source |
How to run
# fastest path: ColabFold (AlphaFold2 + MMseqs2)
pip install colabfold[alphafold]
colabfold_batch input.fasta out_dir/
# or query precomputed structures: https://alphafold.ebi.ac.uk/entry/<UniProt accession>
Regulatory status and intended use
Regulatory status is quoted from the source linked above and can change. Research-use-only models must not be used for clinical decisions.
Limitations and bias
- Static single conformation; poor for intrinsically disordered regions and many point-mutation effects.
- No ligands or complexes with nucleic acids in AlphaFold 2 (see AlphaFold 3).
Sources
This page is educational — it is not medical advice and does not replace consultation with an oncologist. Diagnostic and treatment decisions are made solely by specialist physicians.